Proton pump inhibitors (PPI) have the potential to enhance glucose metabolism and insulin secretion (67), and, therefore, the addition of PPI could help to augment the hypoglycemic effects of DPP-4 inhibitors and then to improve T1D control (68). Here, INS is linked to type 1 diabetes mellitus.